David A Barbie

David A Barbie

UNVERIFIED PROFILE

Are you David A Barbie?   Register this Author

Register author
David A Barbie

David A Barbie

Publications by authors named "David A Barbie"

Are you David A Barbie?   Register this Author

54Publications

1839Reads

43Profile Views

Tumor cGAMP Awakens the Natural Killers.

Immunity 2018 10;49(4):585-587

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2018.10.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390837PMC
October 2018

/-Mutant Lung Cancer: Racing to the Clinic?

Clin Cancer Res 2018 03 17;24(6):1243-1245. Epub 2018 Jan 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-3597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856629PMC
March 2018

Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Cancer Discov 2018 02 3;8(2):196-215. Epub 2017 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809290PMC
February 2018

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer.

Annu Rev Med 2018 01 3;69:333-347. Epub 2017 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-060116-022926DOI Listing
January 2018

Mechanisms of resistance to immune checkpoint inhibitors.

Br J Cancer 2018 01 2;118(1):9-16. Epub 2018 Jan 2.

Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765236PMC
January 2018

Refining Targeted Therapy Opportunities for -Mutant Melanoma.

Cancer Discov 2017 08;7(8):799-801

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0607DOI Listing
August 2017

Tumor SQSTM1 (p62) expression and T cells in colorectal cancer.

Oncoimmunology 2017 31;6(3):e1284720. Epub 2017 Jan 31.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1284720DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384412PMC
January 2017

Inflammation as a driver and vulnerability of KRAS mediated oncogenesis.

Semin Cell Dev Biol 2016 10 11;58:127-35. Epub 2016 Jun 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcdb.2016.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028268PMC
October 2016

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.

Clin Lung Cancer 2015 Sep 7;16(5):e101-4. Epub 2015 Feb 7.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529392PMC
September 2015

Doxycycline: new tricks for an old drug.

Oncotarget 2015 Aug;6(23):19336-7

Buck Institute for Research on Aging, Novato, CA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637276PMC
http://dx.doi.org/10.18632/oncotarget.5111DOI Listing
August 2015

Targeting cytokine networks in KRAS-driven tumorigenesis.

Expert Rev Anticancer Ther 2014 Aug 13;14(8):869-71. Epub 2014 Jun 13.

Department of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2014.928596DOI Listing
August 2014

Targeting pathways downstream of KRAS in lung adenocarcinoma.

Pharmacogenomics 2014 Aug;15(11):1507-18

Department of Medical Oncology & Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.14.108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227881PMC
August 2014

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Blood 2014 Jul 24;124(1):13-23. Epub 2014 Apr 24.

Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany; German Consortium for Translational Cancer Research, Heidelberg, Germany;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-02-558114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190617PMC
July 2014

Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.

Cancer Discov 2014 Apr 20;4(4):452-65. Epub 2014 Jan 20.

Departments of 1Medical Oncology and 2Cancer Biology, Dana-Farber Cancer Institute; 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT, Cambridge; 5MGH Cancer Center, 6Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts; and 7Department of Surgery, Division of Biology and Biomedical Sciences, Washington University, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0646DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980023PMC
April 2014

Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers.

Cancer Discov 2013 Sep 13;3(9):1044-57. Epub 2013 Jun 13.

1Departments of Medical Oncology and 2Cancer Biology; 3Center for Cancer Genome Discovery, Dana-Farber Cancer Institute;4Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; 5Broad Institute of Harvard and MIT, Cambridge, Massachusetts; and 6Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0592DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770815PMC
September 2013

Functional genomics and cancer drug target discovery.

Curr Opin Mol Ther 2010 Jun;12(3):284-93

Dana-Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
June 2010

Systemic mastocytosis: current classification and novel therapeutic options.

Clin Adv Hematol Oncol 2006 Oct;4(10):768-75

Department of Medical Oncology/Hematologic Malignancies at Dana-Farber Cancer Institute and Massachusetts General Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
October 2006

Nuclear tumor suppressors in space and time.

Trends Cell Biol 2005 Jul;15(7):378-85

Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tcb.2005.05.005DOI Listing
July 2005

Eosinophilic gastroenteritis associated with systemic lupus erythematosus.

J Clin Gastroenterol 2004 Nov-Dec;38(10):883-6

Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00004836-200411000-00010DOI Listing
February 2005

Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Proc Natl Acad Sci U S A 2003 Dec 11;100(26):15601-6. Epub 2003 Dec 11.

Pediatric Surgical Research Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.2636900100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC307614PMC
December 2003